ESTRATAB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ESTRATAB (ESTRATAB).
Estrogen replacement therapy. Estrone sulfate and other conjugated estrogens bind to estrogen receptors, activating gene transcription and producing estrogenic effects on various target tissues including the uterus, breast, bone, and cardiovascular system.
| Metabolism | Conjugated estrogens are primarily metabolized in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4 and CYP1A2), followed by conjugation with glucuronic acid or sulfate. Estrone is converted to estradiol and estriol; metabolites are excreted in urine and bile. |
| Excretion | Esterified estrogens are metabolized in the liver and undergo enterohepatic recirculation. Metabolites are excreted primarily in urine as glucuronide and sulfate conjugates (~60-80%), with ~10-20% excreted in feces via bile. Less than 5% is excreted unchanged. |
| Half-life | Estrone sulfate has a terminal half-life of approximately 10-16 hours; estradiol has a shorter half-life of 1-2 hours. Due to conversion to estrone and enterohepatic cycling, clinical effects persist beyond plasma levels. |
| Protein binding | Estrogens are approximately 98-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Volume of distribution: approximately 1-5 L/kg for estrone and estradiol, indicating extensive tissue distribution including breast, adipose, and reproductive tissues. |
| Bioavailability | Oral bioavailability of esterified estrogens is approximately 30-50% due to extensive first-pass metabolism in the liver and gut. |
| Onset of Action | Oral administration: Clinical effects (e.g., menopausal symptom relief) typically begin within 2-4 weeks. Serum estrogen levels rise within 1-2 hours. |
| Duration of Action | Duration of action: 24-48 hours for symptom relief after steady state is achieved (usually within 2-3 weeks). Once-daily dosing maintains continuous effect. |
1 tablet (estrogens 0.625 mg / methyltestosterone 1.25 mg) orally once daily cyclic (3 weeks on, 1 week off) for menopausal symptoms; adjust based on response.
| Dosage form | TABLET |
| Renal impairment | No specific guidelines; use with caution in severe renal impairment as estrogens may be metabolized renally. Monitor fluid balance and electrolytes. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). Reduce dose by 50% in mild to moderate impairment (Child-Pugh A or B) and monitor hepatic function. |
| Pediatric use | Not indicated for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Use lowest effective dose for shortest duration due to increased risk of thromboembolic events, stroke, and dementia in women >65 years. Monitor for endometrial cancer and cardiovascular effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ESTRATAB (ESTRATAB).
| Breastfeeding | Excreted in breast milk; may reduce milk quality and quantity. M/P ratio not determined. Contraindicated in breastfeeding due to potential adverse effects on infant development. |
| Teratogenic Risk | Estrogens are contraindicated in pregnancy. First trimester exposure associated with vaginal adenosis and clear cell adenocarcinoma in female offspring. Second/third trimester use may cause urogenital abnormalities, cardiovascular defects, and increased risk of neurodevelopmental disorders. |
| Fetal Monitoring |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in postmenopausal women. Use adequate diagnostic measures, including endometrial sampling when indicated, to rule out malignancy in women with undiagnosed persistent or abnormal genital bleeding. Do not use estrogen-alone therapy for the prevention of cardiovascular disease or dementia.
| Serious Effects |
["Undiagnosed abnormal genital bleeding","Known, suspected, or history of breast cancer","Known or suspected estrogen-dependent neoplasia","Active or history of venous thromboembolism","Active or history of arterial thromboembolism (e.g., stroke, MI)","Known hypersensitivity to any ingredient","Hepatic impairment or disease","Pregnancy"]
| Precautions | ["Cardiovascular disorders: Increased risk of stroke and deep vein thrombosis (DVT) reported with estrogen-alone therapy.","Malignant neoplasms: Estrogens increase risk of endometrial cancer; risk of breast cancer may increase with duration of use.","Dementia: Estrogen-alone therapy may increase risk of probable dementia in women over 65.","Gallbladder disease: Increased risk requiring surgery.","Hypertriglyceridemia: Elevations may occur; discontinue if persistent.","Fluid retention: Caution in patients with conditions exacerbated by fluid retention.","Hypocalcemia: Caution in hypoparathyroidism.","Ocular effects: Retinal vascular thrombosis; discontinue if papilledema or visual disturbances occur."] |
Loading safety data…
| Monitor for fetal growth restriction, congenital anomalies via ultrasound. Maternal surveillance for thromboembolic events, hypertension, and hepatic dysfunction. |
| Fertility Effects | May impair fertility by inhibiting gonadotropin secretion, disrupting ovulation. Long-term use can cause menstrual irregularities and endometrial atrophy. |
| Food/Dietary | Grapefruit juice may increase estrogen levels by inhibiting CYP3A4 metabolism; avoid concurrent intake. High-fat meals may increase absorption of esterified estrogens; take consistently with or without food to maintain steady levels. |
| Clinical Pearls | EstrataB is a combination esterified estrogens and methyltestosterone product. Monitor liver function tests and lipid profiles due to potential hepatotoxicity and adverse lipid effects from the androgen component. Use with caution in patients with history of thromboembolic disorders, as estrogens increase risk. Androgenic effects may include hirsutism, acne, and voice deepening. |
| Patient Advice | Report any signs of blood clots such as sudden leg pain, chest pain, or shortness of breath immediately. · Notify your doctor if you experience jaundice, dark urine, or abdominal pain as these may indicate liver problems. · Watch for masculinizing effects like deepening voice, excessive hair growth, or acne and discuss with your healthcare provider. · Do not use if pregnant, may become pregnant, or are breastfeeding; use effective contraception if needed. · Take with food to reduce gastrointestinal upset; avoid grapefruit juice as it may increase estrogen levels. |